PrediCare

简体中文

Current Standard of Care

Nowadays, the standard-of-care (SOC) treatment options of advanced stage (IIb and IV) solid cancers (e.g., lung, breast , colon cancer) include different therapeutic options, ranging from standard chemotherapies to novel targeted therapeutics or immunotherapies.

READ MORE
The PrediCare Product

PrediCare is a novel software-based treatment navigation tool, predicting the patient’s disease progression moment. This moment is critical in the patient’s therapeutic timeline, being the key event controlling the change of the treatment plan. PrediCare is designed to be applied in the individual patient treatment course, after each radiological assessment of the tumor, and prior to the next scheduled assessment.

READ MORE
Optimizing Treatment Switch

PrediCare facilitates a treatment line switch just prior to an imminent disease progression. This policy adheres to the National Comprehensive Cancer Network (NCCN) guideline, e.g., for switch maintenance therapy in non-small cell lung cancer, but in contrast to the latter modality, PrediCare enables optimization of the timing of the switch in the treatment line, and thus contributes to better patient outcomes.

READ MORE
Technology

The technology of PrediCare relies on an algorithm which integrates patient level clinical information with a newly-developed machine-learning methodology, which extracts and amplifies biomarker signals for a forthcoming progression event.

READ MORE